Spectranetics Corporation Broadens Laser Catheter Portfolio to Treat Complex Lesions and Chronic Total Occlusions (CTOs)
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
COLORADO SPRINGS, Colo., Aug. 19, 2013 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) today announced the launch of the Turbo Elite® .035 product line extension. The two new catheter sizes – with diameters of 2.3 mm and 2.5 mm – are compatible with a .035" guidewire, augmenting the versatility of the Turbo Elite laser to treat complex lesions including chronic total occlusions (CTOs) in blood vessels above and below the knee.
Help employers find you! Check out all the jobs and post your resume.
COLORADO SPRINGS, Colo., Aug. 19, 2013 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) today announced the launch of the Turbo Elite® .035 product line extension. The two new catheter sizes – with diameters of 2.3 mm and 2.5 mm – are compatible with a .035" guidewire, augmenting the versatility of the Turbo Elite laser to treat complex lesions including chronic total occlusions (CTOs) in blood vessels above and below the knee.
Help employers find you! Check out all the jobs and post your resume.